Post Reply
2801-2820 of 10899
They are collecting their profits. It will resume the uptrend it the rally continues but it may not be today. This is healthy for the stock to propel higher.
gbleng ( Date: 09-Feb-2012 14:05) Posted:
|
After a spectacular result this stock falls 3.5%.... this market is a joke....
Spectacular result. Expect it to skyrocket tomorrow. :)
Got 10 lots @ 1.64 for the result play..
Feb 6 (Reuters) - CIMB began coverage of Singapore drug stent maker Biosensors International with an outperform rating and set a price target of S$1.98.
CIMB said Biosensors is a rising star in the intrusive medical device market and the company has rapidly emerged as a global leader in coronary stents.
Biosensors now owns 25 percent of the drug-eluting stent market in China, CIMB said, adding that the approval for the sale of the company's flagship BioMatrix would swell this number, potentially making it the biggest player in China.
Flagging global sales of drug-eluting stents are also likely to pick up as second-generation stents have demonstrated superior safety and efficacy, CIMB said.
Drug-eluting stents have a medicated coating to help prevent the reclogging of arteries after the stents are inserted in angioplasty procedures.
" Biosensors is in a sweet spot to ride potentially explosive growth in their demand," CIMB said. (Reporting by Eveline Danubrata Editing by Anshuman Daga)
Look at Biosensors, flying past the finishing line. LOL Like a horse race, coming from behind to win handsomely. LOL.
it appears Terumo cardiac & vascular business increase from 106,840 to 118,672 or 12,000 millions of Y. I think that mean about $200M or $155M US. So should be good for BIG royalty!!
| Sunny Side Up - Biosensors International, China Merchants Holdings |
|
What’s cooking
Biosensors International (BIG SP, $1.585, Buy, TP $1.80) – We upgrade Biosensors to Buy from Hold and raise our SOTP-based target price to $1.80 as we think that two emerging trends would help sharpen the company’s growth prospects. The first is Shandong Weigao taking on a more active role in its capacity as Biosensors’ majority shareholder and the second, China’s SFDA approval for BioMatrix should be forthcoming. We therefore assign a higher PER of 18x to Biosensors’ drug-eluting stent business to take into account greater growth potential. |
| Click HEREto download PDF report |
| Singapore Research Team |
I like this Biosensors, though not vested, for its resillience to the market swings, My thinking is that it is a good long term investment if you are choosing to hold one more year from now, you will make good money.
I think this stock need to rest abit. At the current share price, it is already at historical highs. Yes, earnings will grow as it gets the licenses and approvals necessary to sell at more markets. moreover with the acquisition of the remaining stake in JWMS, China will represent a trememndous earnings driver. http://sgxstockpicker.blogspot.com/2012/01/what-have-i-learnt-over-past-three.html
Now at the resistance level, waiting for 8-Feb earnings report. Probably need some good news to break through the resistance. One of the core drivers that drove up the price for past few months is the higher than expected contribution from Noburi stent licensing to Terumo. You can follow Terumo earnings report next week 30-Jan. If Terumo beats estimate for the Cardiovascular products, consider this as a 1-week early indicator that there is a higher chance that Biosensors can post good result too.
Many waiting for it to pull-back???
Anyone know what is happening? Why can't break higher?
BIG merger - since the merger does BIG still need Chinese Minstry of Health approval for stent? or can it be sold through existing channels of JW??
BIG Licensed to Guidant which is now owned by Abbott. Any idea on if or how this impacts BIG's ability to collect royalty?
Abbott Labs Wins Ruling Over J& J, Wyeth in Xience Stent Case on Patents
Abbott Laboratories (ABT) and Medtronic Inc. (MDT) won a federal court ruling that invalidated two patents for heart devices controlled by Johnson & Johnson’s Cordis unit andWyeth (WYE).
U.S. District Judge Joel Pisano in Trenton, New Jersey, ruled Jan. 19 that the patents didn’t fulfill the requirement that they describe what the company claims to have invented, and so were invalid. Cordis and Wyeth had contended that Abbott’s Xience and Medtronic’s Endeavor stents were using the inventions without permission.
The ruling was part of a long-running battle over inventions related to stents, tiny mesh tubes used to prop open heart arteries after they’re cleared of fat. The drug coating limits the growth of scar tissue that could clog the arteries anew. J& J pioneered the market only to lose ground to competitors, and last year it said it would leave the global market altogether.
The two patents, issued in 1996, describe ways to use rapamycin or related medicines on the devices to treat the growth of the scar tissue. New York-based Wyeth owns the patents and licenses them to J& J, which is based in New Brunswick, New Jersey.
Rapamycin, also known as sirolimus and sold by Wyeth (WYE) as Rapamune, is used to coat J& J’s Cypher stent. Wyeth and J& J claimed Abbott, based in Abbott Park, Illinois, and Minneapolis-based Medtronic were using related drugs.
The case also targeted the Promus stent, which uses everolimus to prevent tissue growth. Abbott licenses the Promus stent to Natick, Massachusetts-based Boston Scientific Corp.
In 2010, Boston Scientific agreed to pay J& J $1.73 billion to end other patent lawsuits between the companies over stent technology.
The case is Wyeth v. Abbott Laboratories, 08cv230, and Wyeth v. Medtronic Inc., 08cv1021, both U.S. District Court, District of New Jersey (Trenton).
On Friday, Biosensors re-test the resistance at $1.565 with LOW volume of 2.42 million shares traded.
During the past 10 bars, there have been 6 white candles and 1 black candle for a net of 5 white candles. During the past 50 bars, there have been 27 white candles and 15 black candles for a net of 12 white candles.
RSI & MACD are bullish though RSI in overbought region.
Important Resistance of Biosensors: $1.565
Immediate Support of Biosensors: $1.44
Currently prices are well above 20/50/100/200 days MA.
For the past 5 sessions, ....................... READ MORE
I mean DOW, and BIG can be in a class of its own.
settowin ( Date: 10-Jan-2012 09:49) Posted:
|
Honestly this is one of the best stocks in sg market. I made a huge sum from it. Traded from $1.75 (about there) to $0.28 cents, bought and bought until no money. Luckily it sprang up. Still holding a few, pittance. But since I don't play much sg, I don't research on it nowadays. Concentrate on Dow. Good ranges,constant momentum, and big profit for daring traders who are actively in it.